Presence of isocitrate dehydrogenase mutations may predict clinical response to hypomethylating agents in patients with acute myeloid leukemia

American Journal of Hematology

Volumn 90, Issue 5, 2015, Pages E77-E79

  Emadi, Ashkan ^a   Faramand, Rawan ^a   Carter Cooper, Brandon ^a   Tolu, Seda ^a   Ford, Laurie A ^b   Lapidus, Rena G ^a   Wetzler, Meir ^b   Wang, Eunice S ^b   Etemadi, Arash ^c   Griffiths, Elizabeth A ^b  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; BORTEZOMIB; DECITABINE; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; SAPACITABINE; ANTINEOPLASTIC ANTIMETABOLITE; DNA METHYLTRANSFERASE; IDH1 PROTEIN, HUMAN; ISOCITRATE DEHYDROGENASE; ISOCITRATE DEHYDROGENASE 2, HUMAN;

ACUTE MYELOBLASTIC LEUKEMIA; AGED; ARTICLE; BONE MARROW; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; DNA METHYLATION; DNA SEQUENCE; FEMALE; FOLLOW UP; GENE; GENE MUTATION; HUMAN; HUMAN CELL; IDH1 GENE; IDH2 GENE; LEUKEMIA REMISSION; MALE; MEDICAL RECORD REVIEW; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT RESPONSE; WILD TYPE; AGE; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; GENETICS; GENOTYPE; LEUKEMIA, MYELOID, ACUTE; MUTATION; ODDS RATIO; PATHOLOGY; PROGNOSIS; REMISSION; SEX DIFFERENCE;

AGE FACTORS; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; DNA MODIFICATION METHYLASES; FEMALE; GENOTYPE; HUMANS; ISOCITRATE DEHYDROGENASE; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; ODDS RATIO; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 84928232727     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23965     Document Type: Article

References (27)

1. Cancer Genome Atlas Research N. Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med 2013;368:2059-2074.
2. Figueroa ME, Abdel-Wahab O, Lu C, et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer Cell 2010;18:553-567.
3. Emadi A, Jun SA, Tsukamoto T, et al. Inhibition of glutaminase selectively suppresses the growth of primary acute myeloid leukemia cells with IDH mutations. Exp Hematol 2014;42:247-251.
4. Levis M. Targeting IDH: the next big thing in AML. Blood 2013;122:2770-2771.
5. Fathi AT, Sadrzadeh H, Borger DR, et al. Prospective serial evaluation of 2-hydroxyglutarate, during treatment of newly diagnosed acute myeloid leukemia, to assess disease activity and therapeutic response. Blood 2012;120:4649-4652.
6. Chaturvedi A, Araujo Cruz MM, Jyotsana N, et al. Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 2013;122:2877-2887.
7. Abbas S, Lugthart S, Kavelaars FG, et al. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: Prevalence and prognostic value. Blood 2010;116:2122-2126.
8. Feng JH, Guo XP, Chen YY, et al. Prognostic significance of IDH1 mutations in acute myeloid leukemia: A meta-analysis. Am J Blood Res 2012;2:254-264.
9. Kaminskas E, Farrell A, Abraham S, et al. Approval summary: Azacitidine for treatment of myelodysplastic syndrome subtypes. Clin Cancer Res Off J Am Assoc Cancer Res 2005;11:3604-3608.
10. Duong VH, Komrokji RS, List AF. Update on the pharmacotherapy for myelodysplastic syndromes. Expert Opin Pharmacother 2014;15:1811-1825.
11. Tawfik B, Sliesoraitis S, Lyerly S, et al. Efficacy of the hypomethylating agents as frontline, salvage, or consolidation therapy in adults with acute myeloid leukemia (AML). Ann Hematol 2014;93:47-55.
12. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010;115:453-474.
13. Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the international working group (IWG) response criteria in myelodysplasia. Blood 2006;108:419-425.
14. Patnaik MM, Hanson CA, Hodnefield JM, et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: A mayo clinic study of 277 patients. Leukemia 2012;26:101-105.
15. Paschka P, Schlenk RF, Gaidzik VI, et al. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol Off J Am Soc Clin Oncol 2010;28:3636-3643.
16. Emadi A, Karp JE. The state of the union on treatment of acute myeloid leukemia. Leuk Lymph 2014;55:2423-2425.
17. Klepin HD, Rao AV, Pardee TS. Acute myeloid leukemia and myelodysplastic syndromes in older adults. J Clin Oncol 2014;32:2541-2552.
18. Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol Off J Am Soc Clin Oncol 2012;30:2670-2677.
19. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010;107:7473-7478.
20. Bhatnagar B, Duong VH, Gourdin TS, et al. Ten-day decitabine as initial therapy for newly diagnosed patients with acute myeloid leukemia unfit for intensive chemotherapy. Leuk Lymph 2014;55:1533-1537.
21. Quintas-Cardama A, Ravandi F, Liu-Dumlao T, et al. Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia. Blood 2012;120:4840-4845.
22. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-57.
23. Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 2011;25:1147-1152.
24. Borodovsky A, Salmasi V, Turcan S, et al. 5-azacytidine reduces methylation, promotes differentiation and induces tumor regression in a patient-derived IDH1 mutant glioma xenograft. Oncotarget 2013;4:1737-1747.
25. Turcan S, Fabius AW, Borodovsky A, et al. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT inhibitor decitabine. Oncotarget 2013;4:1729-1736.
26. Jin J, Hu C, Yu M, et al. Prognostic value of isocitrate dehydrogenase mutations in myelodysplastic syndromes: A retrospective cohort study and meta-analysis. PloS One 2014;9:e100206.
27. DiNardo CD, Patel KP, Garcia-Manero G, et al. Lack of association of IDH1, IDH2 and DNMT3A mutations with outcome in older patients with acute myeloid leukemia treated with hypomethylating agents. Leuk Lymph 2014;55:1925-1929.